Lymphoma  >>  Torisel (temsirolimus)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
OPTIMAL, NCT00117598: Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Checkmark P3 data - EHA
May 2012 - May 2012: P3 data - EHA
Checkmark P3 data
Dec 2011 - Dec 2011: P3 data
Completed
3
169
US, Canada, Europe, RoW
Temsirolimus (CCI-779), Investigator's choice
Pfizer
Lymphoma
08/07
01/11
2004-001430-16: An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)

Completed
3
177
Europe, RoW
Temsirolimus IV, CCI-779, Concentrate for solution for infusion
Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development, Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. (A Pfizer Company), WYETH LEDERLE
Mantle Cell Lymphoma, Diseases [C] - Cancer [C04]
 
 
RAY , NCT01646021 / 2012-000601-74: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Checkmark Final 3-year follow-up results from the RAY P3 trial
May 2018 - May 2018: Final 3-year follow-up results from the RAY P3 trial
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark Vs. temsirolimus in patients with relapsed or refractory mantle-cell lymphoma
More
Completed
3
280
Canada, Europe, RoW
Ibrutinib, Temsirolimus
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
06/15
12/16

Download Options